Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.
Paraguay's DINAVISA regulatory framework and growing clinical research infrastructure offer MedTech startups one of the most cost-effective pathways to first-in-human clinical data in the Americas. With Asunción's expanding hospital network, competitive investigator fees, and bioaccess®'s on-the-ground coordination, Paraguay delivers exceptional value for early-stage device studies.
Paraguay is emerging as a highly attractive destination for first-in-human medical device and drug studies, offering the lowest per-patient costs in Latin America combined with a regulatory framework that is increasingly aligned with international standards. DINAVISA (Dirección Nacional de Vigilancia Sanitaria), the country's health regulatory authority, provides a clear pathway for clinical investigation authorization.
Asunción, Paraguay's capital and largest metropolitan area, anchors the country's clinical research infrastructure with modern hospitals, experienced medical professionals, and a patient population that is largely treatment-naïve — a significant advantage for enrollment in first-in-human studies. The city's major medical centers have invested in infrastructure upgrades that support GCP-compliant clinical operations.
bioaccess® is developing Paraguay as a strategic addition to its Latin American site network, leveraging the country's cost advantages and growing investigator pool. For seed-stage and Series A MedTech startups operating with limited clinical budgets, Paraguay offers the opportunity to generate FDA-quality first-in-human data at a fraction of the cost of other markets — without compromising on data quality or regulatory rigor.
Paraguay's Dirección Nacional de Vigilancia Sanitaria (DINAVISA) operates under the Ministry of Public Health and Social Welfare and oversees the authorization of clinical investigations. DINAVISA's regulatory process requires submission of the clinical investigation protocol, investigator brochure, informed consent documents, and proof of adequate insurance coverage. bioaccess® manages the complete regulatory submission and maintains relationships with DINAVISA reviewers to facilitate efficient processing.
Clinical trials in Paraguay require approval from an institutional ethics committee (Comité de Ética en Investigación) before enrollment can begin. Ethics committee reviews typically complete in 4–6 weeks. Paraguay's ethics committees follow ISO 14155 principles and review protocols for scientific merit, risk-benefit assessment, informed consent adequacy, and patient protection measures. bioaccess® coordinates with established ethics committees at partner hospitals in Asunción.
Asunción's medical infrastructure has undergone significant modernization in recent years, with major hospitals investing in surgical suites, imaging capabilities, and clinical research departments. bioaccess® has identified and is pre-qualifying sites in Asunción with investigators experienced in device studies and familiar with GCP requirements. The compact geography of greater Asunción (2.5 million metro population) simplifies patient recruitment and site monitoring logistics.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Paraguay for IDE and regulatory submissions, provided studies are conducted under ISO 14155 guidelines with proper DINAVISA authorization and ethics committee approval. bioaccess® ensures all Paraguayan protocols are designed with FDA submission requirements from the outset, maintaining rigorous source data verification and monitoring standards. (eligibility for FDA submission and review — not a guarantee of clearance or approval)
| Metric | Paraguay 🇵🇾 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory/ethics approval | 4–6 weeks (DINAVISA + EC) | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Cost per patient | $10K–$18K (lowest in LATAM) | $40K–$75K | $35K–$60K |
| Typical 10-patient FIH study | $150K–$250K | $750K–$1.5M | $500K–$900K |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Patient population | Treatment-naïve; Asunción metro ~2.5M | 330M+ | ~450M |
| Regulatory authority | DINAVISA | FDA | EMA / national CAs |
Ranges reflect bioaccess® first-in-human medical device studies. Actual costs and timelines vary by device complexity, therapeutic area, and monitoring requirements.
Paraguay offers the lowest per-patient costs in Latin America, ranging from $10,000–$18,000 depending on study complexity. A 10-patient FIH study typically costs $150K–$250K all-in. These costs include investigator fees, site costs, ethics committee fees, regulatory submissions, and patient-related expenses.
DINAVISA (Dirección Nacional de Vigilancia Sanitaria) is Paraguay's health regulatory authority under the Ministry of Public Health. It oversees clinical investigation authorization, requiring sponsors to submit protocols, investigator credentials, informed consent documents, and insurance documentation. bioaccess® manages the complete DINAVISA submission process.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Paraguay when studies are conducted under ISO 14155 guidelines with proper DINAVISA authorization and ethics committee approval. bioaccess® designs all Paraguayan protocols with FDA submission requirements integrated from the start.
Ethics committee review in Paraguay typically takes 4–6 weeks. Paraguay's institutional ethics committees (Comités de Ética en Investigación) follow ISO 14155 principles and review protocols for scientific merit, risk-benefit balance, and patient protection. bioaccess® coordinates with established ethics committees at partner hospitals.
Paraguay's clinical research infrastructure is growing rapidly, particularly in Asunción where major hospitals have invested in modern surgical suites, imaging capabilities, and research departments. bioaccess® is actively developing and pre-qualifying sites with GCP-trained investigators to support first-in-human device studies.
Paraguay offers the lowest costs in the region ($10K–$18K per patient vs. $15K–$25K in Colombia, $12K–$22K in Panama). While larger markets like Brazil and Colombia offer deeper investigator pools and more established regulatory frameworks, Paraguay provides exceptional value for early-stage startups with limited budgets. bioaccess® recommends Paraguay as part of multi-country strategies or for budget-conscious FIH programs.
All countries we serve · Contact bioaccess® · First-in-Human CRO